Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill

Executive Summary

Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry. 

You may also be interested in...



Rebate Reporting Law May Provide Timely Trigger For US Pricing Debate – In 2023

Newly enacted requirement for US health plans to report granular drug price and rebating data to the government suggests that the great rebate debate of 2017-2020 won’t be over for long. The first public release of aggregated data will likely come in 2023 – and that might be when Congress is ready to take up drug pricing again.

Drug Price Increases Dwarf ACA Donut Hole Fix for High-Cost Meds

A decade after the Obamacare deal to limit patient exposure to the coverage gap, rising list prices are minimizing the impact for patients taking high-cost medicines with large out-of-pocket costs. Possible fixes have received bipartisan support from Congress, but are likely on hold due to the COVID-19 pandemic. 

Drug Industry Perks Mostly Dropped From COVID-19 Bill, But A Big One Remains

Early versions of US Congress's coronavirus relief bill contained a number of policies that would have benefited drug firms, but they didn't make it into the final bill. However, the $2 trillion package does provide pharmaceutical companies with relief from the threat of drug pricing reform until after the 2020 elections.

Related Content

Topics

UsernamePublicRestriction

Register

PS141923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel